26th Sep 2019, New Delhi
On 25 September Wednesday, at the event- TB Harega Desh Jitega organised in New Delhi, the Central TB programme announced the rolling out an all oral Multi Drug Resistant TB regimen across the country starting with four states, based on one of the two new drugs – Bedaquiline or Delamanid – replacing injectable in the treatment regimen.
While the announcement is a welcome step from the Indian government, in a context like India with high prevalence of fluoroquinolones resistance, many DR-TB patients would require both Bedaquilin and Delamanid in the treatment regimen. Without such access, all oral regimen for Pre-XDR and XDR patients will not become a reality.
The issue has already been raised by Indian civil society including TB survivors and activists by a letter in Dec 2018, demanding scale-up for Bedaquilin and Delamanid. The letter can be read here.